(Q36646145)

15 August 2017

1 reference

title

Hematologic effects of AIDS therapies (English)

1 reference

15 August 2017

Hematologic Effects of AIDS Therapies (English)

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30438-6

4 November 2022

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30438-6

4 November 2022

author name string

J. M. Pluda

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1708759

4 November 2022

H. Mitsuya

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1708759

4 November 2022

R. Yarchoan

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1708759

4 November 2022

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=1708759

4 November 2022

publication date

1 April 1991

1 reference

full work available at URL

15 August 2017

https://api.elsevier.com/content/article/PII:S0889858818304386?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30438-6

https://api.elsevier.com/content/article/PII:S0889858818304386?httpAccept=text/plain

4 November 2022

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30438-6

Hematology / Oncology Clinics of North America

4 November 2022

published in

1 reference

15 August 2017

5

1 reference

15 August 2017

2

1 reference

15 August 2017

229-248

1 reference

Oral dextran sulfate (UA001) in the treatment of the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex.

15 August 2017

1

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30438-6

Initial studies on the cellular pharmacology of 2',3'-dideoxyinosine, an inhibitor of HIV infectivity

4 November 2022

2

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30438-6

Trimetrexate for the treatment of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome

4 November 2022

3

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30438-6

Initial studies on the cellular pharmacology of 3'-deoxythymidin-2'-ene (d4T): a potent and selective inhibitor of human immunodeficiency virus

4 November 2022

4

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30438-6

Granulocyte-macrophage colony-stimulating factor enhances neutrophil function in acquired immunodeficiency syndrome patients

4 November 2022

5

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30438-6

Isolation of a T-Lymphotropic Retrovirus from a Patient at Risk for Acquired Immune Deficiency Syndrome (AIDS)

4 November 2022

7

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30438-6

The effect of recombinant human granulocyte-macrophage colony-stimulating factor (rGM-CSF) on 3'-azido-3'-deoxythymidine (AZT)-mediated biochemical and cytotoxic effects on normal human myeloid progenitor cells

4 November 2022

9

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30438-6

Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer

4 November 2022

10

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30438-6

Biological properties of a CD4 immunoadhesin

4 November 2022

13

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30438-6

Designing CD4 immunoadhesins for AIDS therapy

4 November 2022

14

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30438-6

The human hematopoietic colony-stimulating factors

4 November 2022

18

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30438-6

Treatment of serious cytomegalovirus infections with 9-(1,3-dihydroxy-2-propoxymethyl)guanine in patients with AIDS and other immunodeficiencies

4 November 2022

19

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30438-6

Once-daily administration of 2',3'-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. Results of a Phase I trial

4 November 2022

20

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30438-6

Treatment of toxoplasmic encephalitis with intravenous clindamycin

4 November 2022

21

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30438-6

Alteration of zidovudine pharmacokinetics by probenecid in patients with AIDS or AIDS-related complex

4 November 2022

22

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30438-6

Clinical and virological effects of high-dose recombinant interferon-alpha in disseminated AIDS-related Kaposi's sarcoma

4 November 2022

23

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30438-6

Effects of zidovudine in 365 consecutive patients with AIDS or AIDS-related complex

4 November 2022

24

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30438-6

Reversible axonal neuropathy from the treatment of AIDS and related disorders with 2',3'-dideoxycytidine (ddC).

4 November 2022

25

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30438-6

Intralesional vinblastine for oral Kaposi sarcoma in HIV infection

4 November 2022

26

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30438-6

Treatment of the anemia of progressive renal failure with recombinant human erythropoietin

4 November 2022

27

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30438-6

Recombinant human erythropoietin for patients with AIDS treated with zidovudine

4 November 2022

28

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30438-6

A randomized controlled trial of a reduced daily dose of zidovudine in patients with the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group

4 November 2022

29

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30438-6

The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial

4 November 2022

31

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30438-6

Infection and replication of HIV-1 in purified progenitor cells of normal human bone marrow

4 November 2022

32

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30438-6

Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase

4 November 2022

34

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30438-6

Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium

4 November 2022

35

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30438-6

Azidothymidine in the treatment of AIDS

4 November 2022

36

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30438-6

Efficient isolation and propagation of human immunodeficiency virus on recombinant colony-stimulating factor 1-treated monocytes

4 November 2022

39

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30438-6

Azidothymidine associated with bone marrow failure in the acquired immunodeficiency syndrome (AIDS)

4 November 2022

41

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30438-6

Effect of recombinant human granulocyte-macrophage colony-stimulating factor on myelopoiesis in the acquired immunodeficiency syndrome

4 November 2022

42

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30438-6

Interference with HIV-induced syncytium formation and viral infectivity by inhibitors of trimming glucosidase

4 November 2022

43

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30438-6

Pharmacokinetic Analysis of Dextran Sulfate in Rats as Pertains to Its Clinical Usefulness for Therapy of HIV Infection

4 November 2022

45

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30438-6

Synergistic inhibition of human immunodeficiency virus in vitro by azidothymidine and recombinant alpha A interferon.

4 November 2022

46

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30438-6

In vitro inhibition of the infectivity and replication of human immunodeficiency virus type 1 by combination of antiretroviral 2',3'-dideoxynucleosides and virus-binding inhibitors

4 November 2022

47

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30438-6

Recombinant human interferon alfa-A suppresses HTLV-III replication in vitro.

4 November 2022

48

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30438-6

Risk for the acquired immunodeficiency syndrome among thrombocytopenic and nonthrombocytopenic homosexual men seropositive for the human immunodeficiency virus

4 November 2022

49

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30438-6

The effect of azidothymidine on HIV-related thrombocytopenia

4 November 2022

50

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30438-6

In vitro bone marrow toxicity of nucleoside analogs against human immunodeficiency virus

4 November 2022

51

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30438-6

Serious cytomegalovirus disease in the acquired immunodeficiency syndrome (AIDS). Clinical findings, diagnosis, and treatment

4 November 2022

52

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30438-6

Complications of co-trimoxazole in treatment of AIDS-associated Pneumocystis carinii pneumonia in homosexual men

4 November 2022

53

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30438-6

The safety and pharmacokinetics of recombinant soluble CD4 (rCD4) in subjects with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. A phase 1 study.

4 November 2022

54

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30438-6

Lymphoid neoplasia associated with the acquired immunodeficiency syndrome (AIDS). The New York University Medical Center experience with 105 patients (1981-1986)

4 November 2022

55

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30438-6

Combined zidovudine and interferon-alpha therapy in patients with Kaposi sarcoma and the acquired immunodeficiency syndrome (AIDS)

4 November 2022

57

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30438-6

Cytokines alter production of HIV-1 from primary mononuclear phagocytes

4 November 2022

58

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30438-6

Preliminary observations on the effect of recombinant leukocyte A interferon in homosexual men with Kaposi's sarcoma

4 November 2022

60

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30438-6

2',3'-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. A phase I trial

4 November 2022

63

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30438-6

HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy

4 November 2022

65

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30438-6

Treatment of epidemic Kaposi's sarcoma with etoposide or a combination of doxorubicin, bleomycin, and vinblastine.

4 November 2022

66

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30438-6

Foscarnet in the treatment of cytomegalovirus retinitis in acquired immune deficiency syndrome

4 November 2022

67

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30438-6

Survival trends for patients with AIDS.

4 November 2022

68

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30438-6

Treatment of central nervous system toxoplasmosis with pyrimethamine/sulfadiazine combination in 35 patients with the acquired immunodeficiency syndrome. Efficacy of long-term continuous therapy.

4 November 2022

69

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30438-6

Dextran sulfate is poorly absorbed after oral administration.

4 November 2022

71

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30438-6

AIDS commentary. Toxoplasmic encephalitis

4 November 2022

72

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30438-6

Dermatologic complications associated with administration of 2',3'-dideoxycytidine in patients with human immunodeficiency virus infection

4 November 2022

73

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30438-6

Circulating p24 antigen levels and responses to dideoxycytidine in human immunodeficiency virus (HIV) infections. A phase I and II study

4 November 2022

74

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30438-6

The granulocyte-macrophage colony-stimulating factors

4 November 2022

75

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30438-6

Treatment of Kaposi's sarcoma and thrombocytopenia with vincristine in patients with the acquired immunodeficiency syndrome

4 November 2022

77

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30438-6

Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2',3'-dideoxynucleosides

4 November 2022

78

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30438-6

Dextran sulfate suppression of viruses in the HIV family: inhibition of virion binding to CD4+ cells

4 November 2022

79

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30438-6

3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro

4 November 2022

80

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30438-6

Bone marrow toxicity of dideoxyinosine

4 November 2022

81

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30438-6

Autoimmune Thrombocytopenic Purpura in Homosexual Men

4 November 2022

82

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30438-6

Granulocyte-macrophage colony-stimulating factor augments the primary antibody response by enhancing the function of antigen-presenting cells

4 November 2022

83

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30438-6

Pulmonary complications of the acquired immunodeficiency syndrome. Report of a National Heart, Lung, and Blood Institute workshop

4 November 2022

84

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30438-6

The impact of palliative irradiation on the management of patients with acquired immune deficiency syndrome.

4 November 2022

85

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30438-6

Zidovudine for thrombocytopenic purpura related to human immunodeficiency virus (HIV) infection

4 November 2022

86

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30438-6

Pentamidine for the treatment of Pneumocystis carinii pneumonia and other protozoal diseases

4 November 2022

87

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30438-6

4 November 2022

Q28342341

88

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30438-6

Effect of continuous intravenous infusion of zidovudine (AZT) in children with symptomatic HIV infection

4 November 2022

90

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30438-6

Development of non-Hodgkin lymphoma in a cohort of patients with severe human immunodeficiency virus (HIV) infection on long-term antiretroviral therapy

4 November 2022

93

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30438-6

Detection, Isolation, and Continuous Production of Cytopathic Retroviruses (HTLV-III) from Patients with AIDS and Pre-AIDS

4 November 2022

94

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30438-6

Kaposi's sarcoma and the acquired immunodeficiency syndrome: treatment with high and low doses of recombinant leukocyte A interferon

4 November 2022

95

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30438-6

The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial

4 November 2022

96

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30438-6

Recombinant soluble CD4 therapy in patients with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. A phase I-II escalating dosage trial

4 November 2022

97

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30438-6

Studies on the inhibition of mitochondrial DNA replication by 3'-azido-3'-deoxythymidine and other dideoxynucleoside analogs which inhibit HIV-1 replication

4 November 2022

98

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30438-6

Granulocyte-macrophage colony-stimulating factor augments human monocyte fungicidal activity for Candida albicans

4 November 2022

99

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30438-6

Acquired Immune Deficiency Syndrome and Pancytopenia

4 November 2022

101

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30438-6

Zidovudine for the treatment of thrombocytopenia associated with human immunodeficiency virus (HIV). A prospective study. The Swiss Group for Clinical Studies on the Acquired Immunodeficiency Syndrome (AIDS)

4 November 2022

102

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30438-6

Synergistic interaction of 2',3'-dideoxycytidine and recombinant interferon-alpha-A on replication of human immunodeficiency virus type 1.

4 November 2022

103

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30438-6

Vinblastine therapy for Kaposi's sarcoma in the acquired immunodeficiency syndrome.

4 November 2022

104

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30438-6

Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases

4 November 2022

105

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30438-6

Inhibition of human immunodeficiency virus syncytium formation and virus replication by castanospermine

4 November 2022

106

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30438-6

Anemia and erythropoiesis in patients with the acquired immunodeficiency syndrome (AIDS) and Kaposi sarcoma treated with zidovudine

4 November 2022

107

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30438-6

On the mechanism of thrombocytopenic purpura in sexually active homosexual men.

4 November 2022

108

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30438-6

Human granulocyte-macrophage colony-stimulating factor is a neutrophil activator

4 November 2022

109

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30438-6

Trimethoprim-sulfamethoxazole or pentamidine for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A prospective randomized trial

4 November 2022

110

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30438-6

Response of human-immunodeficiency-virus-associated neurological disease to 3'-azido-3'-deoxythymidine

4 November 2022

111

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30438-6

Development of antiretroviral therapy for the acquired immunodeficiency syndrome and related disorders. A progress report

4 November 2022

112

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30438-6

Administration of 3'-azido-3'-deoxythymidine, an inhibitor of HTLV-III/LAV replication, to patients with AIDS or AIDS-related complex

4 November 2022

114

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30438-6

Clinical and basic advances in the antiretroviral therapy of human immunodeficiency virus infection

4 November 2022

115

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30438-6

Clinical pharmacology of 3'-azido-2',3'-dideoxythymidine (zidovudine) and related dideoxynucleosides

4 November 2022

116

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30438-6

In vivo activity against HIV and favorable toxicity profile of 2',3'-dideoxyinosine

4 November 2022

117

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30438-6

Phase I studies of 2',3'-dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine (AZT).

4 November 2022

118

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30438-6

Non-Hodgkin's lymphoma in 90 homosexual men. Relation to generalized lymphadenopathy and the acquired immunodeficiency syndrome

4 November 2022

121

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30438-6

Outbreak of Burkitt's-like lymphoma in homosexual men.

4 November 2022

122

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30438-6

Megakaryocytes of human immunodeficiency virus-infected individuals express viral RNA.

4 November 2022

123

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30438-6

4 November 2022

Identifiers

1 reference